These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 35502015)
21. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. Kammer JA; Katzman B; Ackerman SL; Hollander DA Br J Ophthalmol; 2010 Jan; 94(1):74-9. PubMed ID: 19726422 [TBL] [Abstract][Full Text] [Related]
22. Prostaglandin analogs in ophthalmology. Subbulakshmi S; Kavitha S; Venkatesh R Indian J Ophthalmol; 2023 May; 71(5):1768-1776. PubMed ID: 37203029 [TBL] [Abstract][Full Text] [Related]
23. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Reardon G; Schwartz GF; Mozaffari E Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964 [TBL] [Abstract][Full Text] [Related]
24. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Parrish RK; Palmberg P; Sheu WP; Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078 [TBL] [Abstract][Full Text] [Related]
25. [Comparison of intraocular pressure reducing effects of three prostaglandin eyedrops in open-angle glaucoma]. Huang HL; Sun XH; Xiao M Zhonghua Yan Ke Za Zhi; 2011 Feb; 47(2):109-13. PubMed ID: 21426839 [TBL] [Abstract][Full Text] [Related]
26. [Prostaglandin analogues and central corneal thickness]. Stefan C; Dumitrica DM; Tebeanu E; Nae I; Sapundgieva A; Dragomir L Oftalmologia; 2007; 51(4):95-9. PubMed ID: 18543683 [TBL] [Abstract][Full Text] [Related]
27. A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients. Ranno S; Sacchi M; Brancato C; Gilardi D; Lembo A; Nucci P ScientificWorldJournal; 2012; 2012():804730. PubMed ID: 22606063 [TBL] [Abstract][Full Text] [Related]
28. Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma. Sawada A; Yamamoto T; Takatsuka N Graefes Arch Clin Exp Ophthalmol; 2012 Jan; 250(1):123-9. PubMed ID: 21858678 [TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. Sen E; Nalcacioglu P; Yazici A; Aksakal FN; Altinok A; Tuna T; Koklu G J Glaucoma; 2008 Aug; 17(5):398-402. PubMed ID: 18703951 [TBL] [Abstract][Full Text] [Related]
30. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Eisenberg DL; Toris CB; Camras CB Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S105-15. PubMed ID: 12204706 [TBL] [Abstract][Full Text] [Related]
31. Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma. Mishra D; Sinha BP; Kumar MS Korean J Ophthalmol; 2014 Oct; 28(5):399-407. PubMed ID: 25276082 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis. Tang W; Zhang F; Liu K; Duan X Medicine (Baltimore); 2019 Jul; 98(30):e16597. PubMed ID: 31348303 [TBL] [Abstract][Full Text] [Related]
33. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs. Schwartz GF; Tan J; Kotak S J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264 [TBL] [Abstract][Full Text] [Related]
34. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes]. Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842 [TBL] [Abstract][Full Text] [Related]
35. Comment on Efficacy and tolerability of prostaglandin analogs. Eisenberg D J Glaucoma; 2009 Aug; 18(6):498; author reply 498-9. PubMed ID: 19593206 [No Abstract] [Full Text] [Related]
36. Evaluation of investigator bias in industry-funded clinical trials of latanoprost. Jinapriya D; Anraku A; Alasbali T; Trope GE; Buys YM Can J Ophthalmol; 2011 Dec; 46(6):531-6. PubMed ID: 22153642 [TBL] [Abstract][Full Text] [Related]
37. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Covert D; Robin AL Curr Med Res Opin; 2006 May; 22(5):971-6. PubMed ID: 16709319 [TBL] [Abstract][Full Text] [Related]
38. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M Curr Med Res Opin; 2005 Nov; 21(11):1875-83. PubMed ID: 16307709 [TBL] [Abstract][Full Text] [Related]
39. Factors Related to Prostaglandin-Associated Periorbitopathy in Glaucoma Patients. Patradul C; Tantisevi V; Manassakorn A Asia Pac J Ophthalmol (Phila); 2017; 6(3):238-242. PubMed ID: 28379653 [TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma. Li J; Lin X; Yu M Eur J Ophthalmol; 2015; 25(1):18-26. PubMed ID: 25044139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]